Cytokinetics Announces That the European Medicines Agency Has Granted CK-2017357 Orphan Medicinal Product Designation for the Treatment of Amyotrophic Lateral Sclerosis

Cytokinetics, Incorporated

announced today that the European Medicines Agency has granted the company's fast skeletal muscle troponin activator CK-2017357 orphan medicinal product designation for the treatment of amyotrophic lateral sclerosis, also commonly known as Lou Gehrig's Disease. CK-2017357 is the lead drug candidate that has emerged from the Cytokinetics' skeletal sarcomere activator program. CK-2017357 is currently the subject of an ongoing Phase II clinical development program in patients with ALS.